SYK and acute myeloid leukemia: Acute myeloid leukemia (AML) was sensitive to tamatinib (targeting SYK) and tipifarnib (targeting farnesyl protein transferase), and marginal zone lymphoma (MZL) was resistant to BCR inhibitors and other kinase inhibitors, a result consistent with prevalent reliance of MZL on NF-κB–activating mutations (30).